Melanotan 2 is one peptide that acts on a whole family of receptors — and that single fact explains everything it does.

The short version

Melanotan 2 is a lab-made copy of a natural body signal called alpha-MSH (a hormone that tells skin cells to make pigment). It is a single small peptide that switches on a whole set of related receptors — the controls for skin color, appetite, and sexual function all at once. That is why people who use it report a tan, less hunger, and changes in sex drive from the same injections.

It has never been approved as a medicine or a cosmetic anywhere. The human evidence is thin: a few small early studies in a handful of volunteers. Most of the rest of the data comes from rats and mice. Alongside the reported tan, the published record also includes real harms — darkening and new moles, a few melanoma cases, kidney and muscle injury, and prolonged painful erections. What people actually report, including the downsides, is on the effects page. This site summarizes that literature, plainly and with sources.

What the Melanotan 2 literature has measured

Melanotan 2 (Melanotan II, MT-2, MT-II) is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH), the natural ligand for the melanocortin receptors. It was designed in the late 1980s at the University of Arizona to be a superpotent, enzyme-resistant melanotropic agent ^[1], ^[3]. Its defining property is breadth: it is a non-selective agonist (an activator) of the melanocortin receptors MC1R through MC5R ^[11]. One molecule, five switches.

That breadth is the through-line of the entire research record. Activating MC1R on pigment cells drives skin and hair darkening without sunlight ^[1]. Activating MC4R in the brain suppresses appetite ^[5] and triggers erections ^[2]. The same compound does all of it, which is both why it interested researchers and why its effects are hard to contain.

The controlled human data are limited. A pilot Phase I study in 3 male volunteers produced measurable pigmentation after only five low subcutaneous doses ^[1]. A placebo-controlled crossover study in 10 men with psychogenic erectile dysfunction produced clinically apparent erections in 8 of 10, with mean tip-rigidity duration of 38.0 minutes versus 3.0 minutes on placebo ^[2]. No Phase II or Phase III trial of Melanotan 2 itself has ever been completed ^[1], ^[3].

One receptor family, several effects

The melanocortin receptors are a family of five G-protein-coupled receptors. Each governs a different system: MC1R controls pigmentation, MC4R controls appetite and sexual function, MC3R contributes to energy balance, and MC5R acts on glands ^[11]. Because Melanotan 2 activates all of them rather than selecting one, its effects span pigment, food intake, and sexual behavior in the same dose.

This is the precise point where Melanotan 2 differs from its better-known relatives. Afamelanotide (Melanotan I) is a more MC1R-selective analog approved for a rare light-sensitivity disorder; bremelanotide (PT-141) was engineered from the Melanotan 2 scaffold toward MC4R-driven sexual effects ^[3]. The full comparison and the receptor logic behind it are laid out in the melanotan 2 mechanism of action page.

What this site is — and is not

This is an editorial digest. It reads the peer-reviewed Melanotan 2 literature and reports what the studies measured, organized by mechanism and cited to source. It is not a clinic, not a vendor, and not a set of instructions.

Melanotan 2 has no approved human use ^[3]. It carries documented serious harms in case reports — renal infarction ^[4], rhabdomyolysis, priapism, and melanoma among them. The honest account of those harms sits on the Melanotan 2 effects page, the study-by-study record is on the Melanotan 2 research page, and every source is listed on the Melanotan 2 references page. Doses appear only as study-design facts, never as guidance.